Published on
September 23, 2024
In the ultra-competitive world of cancer medicines, Summit Therapeutics is a relative minnow. The 21-year-old biotech company has just 130 employees, no revenue and no approved drugs. But in the past two weeks, its market capitalisation has exploded following positive news about its most promising drug candidate.
Under the leadership of Summit Therapeutics Co-CEO Maky…
Read More…
Source: https://www.forbes.com.au/news/billionaires/this-immigrant-just-became-a-biotech-billionaire/